TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
MedPage Today published a roundup of seven health-related comments from its reporters on Oct. 25, 2026. The topics include dengue outbreaks, pregnancy exposure to dupilumab, multiple sclerosis diagnosis, menopause treatments, advance care planning and a small Parkinson’s disease trial.
MedPage Today published a seven-quote roundup on Oct. 25, 2026, capturing clinicians’ and researchers’ reactions to health developments ranging from dengue outbreaks to early research on psilocybin and Parkinson’s disease. The comments point to several separate stories; the roundup itself does not report a single new study or policy change.
The quotes cover infectious disease, pregnancy and neurology, as well as menopause care and medical decision-making. Adam Waickman of SUNY Upstate Medical University commented on dengue outbreaks in Florida and the possibility of further spread in the United States. Christina Chambers of the University of California San Diego discussed whether exposure to dupilumab, sold as Dupixent, early in life could affect a child’s later risk of atopic conditions. The roundup says data indicated exposure during pregnancy appeared safe, while the longer-term question remains open.
Other comments address clinical diagnosis and treatment. Cleveland Clinic neurologist Marisa McGinley said incorrect multiple sclerosis diagnoses do occur, in the context of actress Christina Applegate’s misdiagnosis. Lynn Sinitsky of West Hertfordshire Teaching Hospitals NHS Trust discussed an exceptionally rare infant case in which a second colon was found after constipation had been treated as straightforward. Harvard’s JoAnn Manson characterized a meta-analysis finding that non-hormonal menopause drugs may ease sleep disturbances as good news for women.
The final two topics concern care planning and preliminary research. Angelo Volandes of Dartmouth Health discussed a video decision-support tool that research found increased documentation of advance care planning among patients nearing kidney failure. Ellen Bradley of the University of California San Francisco described a small trial in Parkinson’s disease that linked psilocybin with reduced markers of systemic inflammation and mitochondrial stress. The roundup provides no trial size, effect estimates or detailed methods for that research.
Seven Topics, Different Evidence Stages
The roundup brings together issues that can affect patients and clinicians, but the evidence behind them varies widely. Dengue spread, medication exposure in pregnancy and diagnostic errors involve questions about risk, recognition and follow-up. The comments are useful as pointers to those discussions, but they do not replace the underlying reporting or studies.
Several remarks also underline the difference between a promising finding and an established clinical recommendation. A meta-analysis and a small exploratory trial are not interchangeable forms of evidence, and a research result does not by itself establish how a treatment should be used. The advance-care-planning tool, meanwhile, addresses whether patients’ preferences are documented as they approach kidney failure, a practical issue in care decisions.
For readers, the main value is a concise map of the week’s health coverage. Each quote needs its original evidence and context before it can support conclusions about individual care, population risk or future treatment.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
As an affiliate, we earn on qualifying purchases.
The Stories Behind the Quotes
MedPage Today describes the item as a collection of quotable remarks heard by its reporters, rather than a new evidence review. The page lists comments from seven experts and links them to distinct subjects: dengue in Florida, dupilumab exposure during pregnancy and early life, an incorrect MS diagnosis, a rare congenital colon finding, menopause-related sleep symptoms, kidney-failure care planning and a psilocybin study in Parkinson’s disease.
The short format leaves out much of the information needed to assess each subject independently. For example, the excerpt does not identify the scale or locations of the dengue outbreaks, provide details of the pregnancy data, or give the number of participants in the Parkinson’s trial. It also does not include the full results or limitations of the menopause meta-analysis and care-planning research. Those details would need to be checked against the original reports and studies.
““This is good news for women.””
— JoAnn Manson, MD, MPH, DrPH, of Harvard Medical School
What the Roundup Leaves Open
The collection does not provide the underlying studies’ full methods, participant numbers, effect sizes or limitations, so it cannot establish how broadly any result applies. Pregnancy exposure to dupilumab was described as appearing safe, but the longer-term effect of early-life exposure on atopic conditions was explicitly presented as unresolved.
Other points also require care. The excerpt does not quantify dengue cases or describe the basis for predicting further spread. It gives no clinical details about the infant’s rare anatomy or the circumstances of Applegate’s incorrect diagnosis. The menopause finding and advance-care-planning result are summarized without their full study details. The psilocybin finding is from a small trial and concerns biological markers; the excerpt does not say whether symptoms or disease progression changed.
Follow the Evidence in Each Story
The immediate next step for readers seeking clinical or public-health implications is to consult the original reports and studies behind each quotation. Those materials would clarify the scale of the dengue outbreaks, the evidence on medication exposure, and the strength and limits of the treatment and care-planning findings. The roundup announces no shared follow-up date or next milestone across the seven topics.
Further research will be needed to answer questions the quotes leave open, including longer-term outcomes after early dupilumab exposure and whether the psilocybin trial’s biomarker changes have meaningful clinical implications. Any updates will depend on new reporting, study results or public-health information; none are specified in the roundup.
Key Questions
What did MedPage Today publish?
It published a weekly collection of seven quotations from clinicians and researchers, tied to separate health stories, on Oct. 25, 2026.
Does the roundup report one new study?
No. It brings together comments about several different topics and mentions research findings, but it is not a single study report.
What did the roundup say about dupilumab and pregnancy?
It says available data indicated exposure during pregnancy appeared safe. Whether early-life exposure affects a child’s later risk of atopic conditions remains an open question, according to Christina Chambers.
What was reported about psilocybin and Parkinson’s disease?
Ellen Bradley described a small trial that linked psilocybin with reduced markers of systemic inflammation and mitochondrial stress. The excerpt does not give the trial size or establish a clinical benefit.
When was the roundup published?
MedPage Today’s page is dated October 25, 2026.
Source: rss
